Russell Investments Group, Ltd. - ESPERION THERAPEUTICS INC NE ownership

ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2022. The put-call ratio across all filers is 0.24 and the average weighting 0.2%.

Quarter-by-quarter ownership
Russell Investments Group, Ltd. ownership history of ESPERION THERAPEUTICS INC NE
ValueSharesWeighting
Q3 2023$84,606
+327.2%
86,334
+505.9%
0.00%
Q2 2023$19,807
-42.2%
14,250
-33.8%
0.00%
Q1 2023$34,246
-68.1%
21,539
+24.8%
0.00%
Q4 2022$107,479
-90.5%
17,252
-81.7%
0.00%
-100.0%
Q3 2021$1,137,000
+28.6%
94,505
+199.4%
0.00%0.0%
Q1 2021$884,000
-22.9%
31,565
-28.4%
0.00%0.0%
Q4 2020$1,146,000
-60.2%
44,064
-43.1%
0.00%
-66.7%
Q3 2020$2,877,000
+10.1%
77,439
+51.8%
0.01%0.0%
Q2 2020$2,613,000
+57.6%
51,028
-3.0%
0.01%
+50.0%
Q1 2020$1,658,000
-45.4%
52,587
+3.1%
0.00%
-33.3%
Q4 2019$3,039,000
+176.3%
51,004
+70.2%
0.01%
+200.0%
Q3 2019$1,100,000
+3337.5%
29,962
+4267.6%
0.00%
Q2 2019$32,000
-93.3%
686
-93.4%
0.00%
-100.0%
Q4 2018$480,000
-12.9%
10,441
-15.9%
0.00%0.0%
Q3 2018$551,000
+698.6%
12,422
+598.3%
0.00%
Q2 2018$69,000
-46.5%
1,7790.0%0.00%
Q1 2018$129,000
-21.8%
1,779
-27.2%
0.00%
Q4 2017$165,000
-86.9%
2,444
-90.3%
0.00%
-100.0%
Q3 2017$1,257,000
+17.3%
25,072
+8.3%
0.00%0.0%
Q2 2017$1,072,000
+11.6%
23,159
-14.9%
0.00%0.0%
Q1 2017$961,00027,2130.00%
Other shareholders
ESPERION THERAPEUTICS INC NE shareholders Q4 2022
NameSharesValueWeighting ↓
Meditor Group Ltd 2,818,835$59,618,00021.09%
Bellevue Group AG 4,519,164$95,580,0000.93%
PLATINUM INVESTMENT MANAGEMENT LTD 1,713,176$36,234,0000.84%
Rhenman & Partners Asset Management AB 572,267$12,103,0000.82%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 64,434$1,363,0000.45%
Boxer Capital, LLC 500,000$10,575,0000.37%
EMC Capital Management 27,566$583,0000.33%
WASATCH ADVISORS LP 3,766,935$79,671,0000.32%
Avidity Partners Management LP 400,000$8,460,0000.23%
Cinctive Capital Management LP 186,170$3,937,0000.18%
View complete list of ESPERION THERAPEUTICS INC NE shareholders